Register Login

Foghorn Therapeutics Inc (FHTX)

(90% Positive) Foghorn Therapeutics Inc (FHTX) Announces Enrollment Update for million Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 7:57 p.m.

    📋 Foghorn Therapeutics Inc (FHTX) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 08:50:28

    Event Type: Clinical Trial Update

    Event Details:

    Foghorn Therapeutics Inc (FHTX) Announces Clinical Trial Update Foghorn Therapeutics Inc (FHTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: million, fund
    • Diseases/Conditions: an equity financing
    • Clinical Stage: Phase 1
    • Collaboration: BVF Partners
      • targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary, scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn. Forward-Looking Statements This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s ongoing Phase 1 trial of FHD-909 in SMARCA4-mutated cancers, preclinical product candidates, expected timing of clinical data, expected cash runway, expected timing of regulatory filings, and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024
      • anticipated in 2026
      • expected in 2026

    🔬 Clinical Development Pipeline (Foghorn Therapeutics Inc):

    Product Type Development Stage Therapeutic Area Source
    FHD-286 DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Venetoclax DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Decitabine DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Alopecia, Androgenetic ClinicalTrials.gov
    TDM-105795 DRUG Phase PHASE1 Alopecia, Androgenetic ClinicalTrials.gov
    Q-Cells BIOLOGICAL Phase PHASE1 Transverse Myelitis ClinicalTrials.gov
    FHD-609 DRUG Phase PHASE1 Advanced Synovial Sarcoma ClinicalTrials.gov
    Low Dose Cytarabine DRUG Phase PHASE1 Advanced Hematologic Malignancy ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Foghorn Therapeutics Inc
    • Ticker Symbol: FHTX

Search

News categories